Synthesis and Characterization of Process-Related Impurities of Antihypertensive Drug Olmesartan Medoxomil

Olmesartan medoxomil (1) is the latest angiotensin receptor antagonist approved by the FDA for the treatment of hypertension. During the process development of olmesartan medoxomil, three process-related impurities were observed along with the final API. These impurities were identified as isopropyl...

Full description

Bibliographic Details
Main Authors: G. Venkanna, G. Madhusudhan, K. Mukkanti, A. Sankar, Y. Sampath Kumar, G. Venakata Narayana
Format: Article
Language:English
Published: Hindawi Limited 2013-01-01
Series:Journal of Chemistry
Online Access:http://dx.doi.org/10.1155/2013/516459
Description
Summary:Olmesartan medoxomil (1) is the latest angiotensin receptor antagonist approved by the FDA for the treatment of hypertension. During the process development of olmesartan medoxomil, three process-related impurities were observed along with the final API. These impurities were identified as isopropyl olmesartan (12), dimedoxomil olmesartan (19), dibiphenyl olmesartan (17). The present work describes the synthesis and characterization of all these three impurities.
ISSN:2090-9063
2090-9071